| Dr Jessica Ann Henderson, PT | |
|
3450 Cobb Pkwy Nw Ste 220, Acworth, GA 30101-8352 | |
| (770) 974-1978 | |
| Not Available |
| Full Name | Dr Jessica Ann Henderson |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 19 Years |
| Location | 3450 Cobb Pkwy Nw Ste 220, Acworth, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225121031 | NPI | - | NPPES |
| 7211905 | Medicaid | NC |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Independent Physical Therapy Of Georgia Llc | 2961312244 | 430 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that on July 26, 2010 it received a letter from the NYSE Amex LLC, stating that PharmAthene is not in compliance with the continued listing standards specified in Sections 1003(a)(i), (ii) and (iii) of the NYSE Amex Company Guide, because it has stockholders' equity of less than $2.0 million, $4.0 million and $6.0 million and losses from continuing operations and/or net losses in two of its three most recent fiscal years, three of its four most recent fiscal years and its five most recent fiscal years, respectively.
New research at Washington University School of Medicine in St. Louis points to a common species of bacteria as an important contributor to bacterial vaginosis, a condition linked to preterm birth and increased risk of sexually transmitted diseases.
Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treatment of osteoarthritis, announced today the closing of a $10M Series B financing led by US Venture Partners (USVP).
The World Health Organization (WHO) has released a notification regarding antibiotic usage and resistance this week. The organization has warned that some countries have a very high consumption of antibiotics and there is a shortage in several regions worldwide. This disparity has led to misuse that had spread antibiotic resistance, the WHO says.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.
› Verified 6 days ago
| Entity Name | Independent Physical Therapy Of Georgia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780636068 PECOS PAC ID: 2961312244 Enrollment ID: O20040303000396 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that on July 26, 2010 it received a letter from the NYSE Amex LLC, stating that PharmAthene is not in compliance with the continued listing standards specified in Sections 1003(a)(i), (ii) and (iii) of the NYSE Amex Company Guide, because it has stockholders' equity of less than $2.0 million, $4.0 million and $6.0 million and losses from continuing operations and/or net losses in two of its three most recent fiscal years, three of its four most recent fiscal years and its five most recent fiscal years, respectively.
New research at Washington University School of Medicine in St. Louis points to a common species of bacteria as an important contributor to bacterial vaginosis, a condition linked to preterm birth and increased risk of sexually transmitted diseases.
Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treatment of osteoarthritis, announced today the closing of a $10M Series B financing led by US Venture Partners (USVP).
The World Health Organization (WHO) has released a notification regarding antibiotic usage and resistance this week. The organization has warned that some countries have a very high consumption of antibiotics and there is a shortage in several regions worldwide. This disparity has led to misuse that had spread antibiotic resistance, the WHO says.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.
› Verified 6 days ago
| Entity Name | Advance Rehabilitation & Consulting Limited Partnership |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235434283 PECOS PAC ID: 4082890645 Enrollment ID: O20110609000322 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that on July 26, 2010 it received a letter from the NYSE Amex LLC, stating that PharmAthene is not in compliance with the continued listing standards specified in Sections 1003(a)(i), (ii) and (iii) of the NYSE Amex Company Guide, because it has stockholders' equity of less than $2.0 million, $4.0 million and $6.0 million and losses from continuing operations and/or net losses in two of its three most recent fiscal years, three of its four most recent fiscal years and its five most recent fiscal years, respectively.
New research at Washington University School of Medicine in St. Louis points to a common species of bacteria as an important contributor to bacterial vaginosis, a condition linked to preterm birth and increased risk of sexually transmitted diseases.
Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treatment of osteoarthritis, announced today the closing of a $10M Series B financing led by US Venture Partners (USVP).
The World Health Organization (WHO) has released a notification regarding antibiotic usage and resistance this week. The organization has warned that some countries have a very high consumption of antibiotics and there is a shortage in several regions worldwide. This disparity has led to misuse that had spread antibiotic resistance, the WHO says.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica Ann Henderson, PT 6397 Lee Hwy Ste 300, Chattanooga, TN 37421-4915 Ph: () - | Dr Jessica Ann Henderson, PT 3450 Cobb Pkwy Nw Ste 220, Acworth, GA 30101-8352 Ph: (770) 974-1978 |
News Archive
PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced that on July 26, 2010 it received a letter from the NYSE Amex LLC, stating that PharmAthene is not in compliance with the continued listing standards specified in Sections 1003(a)(i), (ii) and (iii) of the NYSE Amex Company Guide, because it has stockholders' equity of less than $2.0 million, $4.0 million and $6.0 million and losses from continuing operations and/or net losses in two of its three most recent fiscal years, three of its four most recent fiscal years and its five most recent fiscal years, respectively.
New research at Washington University School of Medicine in St. Louis points to a common species of bacteria as an important contributor to bacterial vaginosis, a condition linked to preterm birth and increased risk of sexually transmitted diseases.
Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treatment of osteoarthritis, announced today the closing of a $10M Series B financing led by US Venture Partners (USVP).
The World Health Organization (WHO) has released a notification regarding antibiotic usage and resistance this week. The organization has warned that some countries have a very high consumption of antibiotics and there is a shortage in several regions worldwide. This disparity has led to misuse that had spread antibiotic resistance, the WHO says.
CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.
› Verified 6 days ago